Provectus Pharma (PVCT) 0.11 $PVCT Provectus

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2016 at 5:11 AM

Provectus Pharma (PVCT) 0.11 $PVCT

Provectus Biopharmaceuticals to Present at Rodman & Renshaw's 18th Annual Global Investment Conference
BusinessWire - Thu Sep 08, 5:00AM CDT
--Conference at Lotte New York Palace Hotel, September 11-13, 2016
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Announces Closing of Public Offering
BusinessWire - Tue Aug 30, 3:01PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) ("Provectus" or the "Company"

, a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has completed its public offering of 240,000 shares of Series B Convertible Preferred Stock and warrants to purchase 24,000,000 shares of common stock at a price to the public of $25.00 for a combination of one share of Series B Convertible Preferred Stock and 100 warrants to purchase one share of common stock each. The warrants have an exercise price of $0.275 per share, are exercisable immediately and will expire on August 30, 2021.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Announces Pricing of Public Offering to Raise $6 Million
BusinessWire - Thu Aug 25, 8:25AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com) ("Provectus" or the "Company"

, a clinical-stage oncology and dermatology biopharmaceutical company, today announced the pricing of a "best efforts" public offering of 240,000 shares of Series B Convertible Preferred Stock (which are initially convertible into an aggregate of 24,000,000 shares of common stock) and warrants initially exercisable to purchase an aggregate of 24,000,000 shares of common stock with a public offering price of $25.00 for a combination of one share of Series B Convertible Preferred Stock and a warrant to purchase one share of common stock. The warrants have an exercise price of $0.275 per share, are exercisable immediately, and will expire on August 30, 2021. The Company expects to receive gross proceeds of approximately $6 million, before deducting placement agent fees and commissions and other estimated offering expenses.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Announces Proposed Public Offering of Preferred Stock and Warrants
BusinessWire - Wed Aug 24, 3:05PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com) ("Provectus" or the "Company"

, a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it intends to offer and sell shares of its Series B Convertible Preferred Stock and warrants to purchase common stock, subject to market and other conditions, in a "best efforts" public offering. Provectus intends to use the net proceeds of the offering for clinical development, working capital and general corporate purposes.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Receives Patent from USPTO Related to Rose Bengal Analogs
BusinessWire - Tue Aug 23, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

today announced that it has received a U.S. patent covering additional aspects of its process for synthesizing halogenated xanthenes, the family of compound to which rose bengal belongs. The patent covers use of certain halogenated xanthenes in pharmaceutical compositions and as medicaments.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 09, 4:05PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

today announced its financial results for the quarter ended June 30, 2016.
PVCT: 0.11 (+0.01)

Investor Calendar Invites You to the Provectus Biopharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Wednesday, August 10, 2016
ACCESSWIRE - Tue Aug 09, 3:11PM CDT
KNOXVILLE, TN / ACCESSWIRE / August 9, 2016 / Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) will host a live conference call and webcast to discuss the results of the second quarter 2016, to be held Wednesday, August 10, 2016 at 4:00 PM Eastern Time.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for Medical Oncology 2016 Congress
BusinessWire - Mon Aug 01, 5:00AM CDT
--Congress Scheduled to Run October 7-11, 2016, Copenhagen, Denmark
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Annual Meeting of American Society of Clinical Oncology Now Available Online
BusinessWire - Thu Jun 09, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, today announced that the poster presented at the Annual Meeting of the American Society of Clinical Oncology is now available online.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Publication of Article on PV-10 for In-Transit Melanoma in Journal of Surgical Oncology
BusinessWire - Tue Jun 07, 3:00PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, today announced that an article on the use of PV-10 for in-transit melanoma has been published by the Journal of Surgical Oncology. It expands on a presentation on the same topic given at the Royal Australasian College of Surgeons 85th Annual Scientific Congress, which was held 2-6 May 2016, in Brisbane, Australia.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA
BusinessWire - Tue Jun 07, 5:00AM CDT
--BIO International Convention Runs June 6-9, 2016
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page
BusinessWire - Wed Jun 01, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, announced today the launch of its newly redesigned website at www.Provectusbio.com as well as the company's official Facebook page at www.facebook.com/Provectusbio.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Abstract Available on PV-10 Plus Radiotherapy in Melanoma
BusinessWire - Thu May 19, 3:00PM CDT
--ASCO Meeting Runs June 3-7, 2016, Chicago, Illinois
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Abstract Available Online of Trials in Progress; Abstract for Poster Presentation at ASCO Annual Meeting
BusinessWire - Thu May 19, 5:00AM CDT
--ASCO Meeting Runs June 3-7, 2016, Chicago, Illinois
PVCT: 0.11 (+0.01)

StockNewsNow.com Publishes May 2016 Update SNNLive Video Interview with Provectus Biopharmaceuticals, Inc.
PR Newswire - Tue May 17, 6:55AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Peter R. Culpepper, Interim CEO and COO of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), specializes in developing oncology and dermatology therapies, according to the company's website (see here: www.ProvectusBio.com). The video interview was recorded on Wednesday, May 4th, 2016, at the Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Publication of Article in Oncotarget Detailing PV-10's Immuno-Ablative Mechanism of Action
BusinessWire - Fri May 13, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, today announced that an article has been published detailing the immuno-ablative mechanism of action of PV-10, the Company's novel investigational drug for cancer.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 5:12PM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT) (www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

, today announced its financial results for the first quarter 2016 ended March 31, 2016.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 pm Eastern Daylight Time
BusinessWire - Wed May 04, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"

, announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4 pm Eastern Daylight Time.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery
BusinessWire - Thu Apr 28, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (NYSE MKT

VCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"

, announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2-6 May 2016, in Queensland, Australia.
PVCT: 0.11 (+0.01)

Provectus Biopharmaceuticals to Participate in Panel at Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact
BusinessWire - Wed Apr 27, 5:00AM CDT
--Conference Runs April 28-30, 2016, in Vatican City
PVCT: 0.11 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

PenFed Fuels Aggie Spirit with Blackout Game Activation

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Interactive Donor Recognition: Beyond GivingTuesday

Crafting Stories That Endure You ever notice how some things just fade away after the holidays? Schools don't want their donor stories to go out like last year's tinsel. Rocket Alumni Solutions strikes right at the core of this concern. They recommend crafting donor recognition that lasts beyond GivingTuesday, by anchoring the story in the school's community. This isn't...

Navigating Roof Damage Insurance Claims: Key Insights

No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...

Chime Joins S&P MidCap 400 Amid Merger Jostle

By Lucas Young Updated Nov 13, 2026 Category News Views 194

Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Thanksgiving in Outer Banks: Unique Traditions Await

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

IM Cannabis's Third Quarter Financial Jolt

By Caleb Price Updated Nov 13, 2026 Category News Views 143

IM Cannabis Takes a Hit, But Seeks New Angles Diving into IM Cannabis's (NASDAQ: IMCC) latest financial splash is like reading a weathered old map of the stock market. The third quarter of 2026 wasn't kind to this little cannabis outfit. Revenues have nosedived to C$1.65 million from last year's C$5.08 million. It's not just the typical bad quarter blues; it's a solid...

Gemmy's Holiday Lights: Bright Ideas for 2026

By Hannah Lewis Updated Nov 13, 2026 Category News Views 174

Deep in the heart of Dallas, Gemmy Industries is out to sprinkle a bit of magic over the holiday season for 2026. This ain't your grandma's string lights we're talkin' about here. We're diving headfirst into a new world of seasonal decor with tech-driven lights that look like they came straight outta a winter wonderland. And hey, if Walmart's set to host this lineup, you...